Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure

International Urology and Nephrology

Volumn 29, Issue 3, 1997, Pages 377-383

  Cakar N ^a   Ekim, M ^a   Tumer N ^a   Yalcinkaya F ^a   Akar, N ^a   Onaran, H O ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; ERYTHROPOIESIS; FEMALE; HUMAN; MALE; PERITONEAL DIALYSIS;

EID: 0030815554     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02550939     Document Type: Article

References (20)

1. Eschbach, J. W., Adamson, J. W.: Recombinant human erythropoietin: Implications for nephrology. Am. J. Kidney Dis., 11, 203 (1988).
2. Eschbach, J. W., Adamson, J. W.: Guidelines for recombinant human erythropoietin therapy. Am. J. Kidney Dis., 14, 2 (1989).
3. Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., Adamson, J. W.: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N. Engl. J. Med., 316, 73 (1984).
4. Winearls, C. G., Oliver, D. O., Pippard, M. J., Reid, C., Downing, M. R., Cotes, P. M.: Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet, ii, 1175 (1986).
5. Hughes, R. T., Cotes, P. M., Oliver, D. O., Pippard, P. R., Royston, P., Stevens, J. M., Strong, C. A., Tam, R. C., Winearls, C. G.: Correction of the anemia of chronic renal failure with erythropoietin: Pharmacokinetic studies in patients on haemodialysis and CAPD. Contrib. Nephrol., 76, 122 (1989).
6. Stockhenhuber, F., Loibl, U., Gottsauner-Wolf, M., Jahn, C., Manker, W., Meisl, Th. F., Balcke, P.: Pharmacokinetic s and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment and continuous ambulatory peritoneal dialysis. Nephron, 59, 399 (1991).
7. Benet, L. Z., Massoud, N.: Pharmacokinetics. In: Benet, L. Z. (ed.): Pharmacokinetic Basis for Drug Treatment. Raven Press, New York 1984, p. 1.
8. Chandra, M., Clemons, G. K., Mc Vigar, M., Wilkes, B., Bluestone, A. P., Mailloux, L. U., Mossey, R. T.: Serum erythropoietin levels and hematocrit in end-stage renal disease: Influence of the mode of dialysis. Am. J. Kidney Dis., 12, 208 (1988).
9. Chandra, M., Clemons, G., Shadev, I., Mc Vigar, M., Bluestone, P.: Intraperitoneal production of erythropoietin with continuous ambulatory peritoneal dialysis. Pediatr. Nephrol., 7, 281 (1993).
10. Zappacosta, A., Caro, J., Erslev, A.: Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Am. J. Med., 72, 53 (1982).
11. De Klerk, G., Wilmink, J. M., Rosengarten, P. C. J., Vet, R. J. W. M., Goudsmith, R.: Serum erythropoietin (ESF) titers in anemia of chronic renal failure. J. Lab. Clin. Med., 100, 720 (1982).
12. Mc Gonigle, R. J. S., Husserl, F., Wallin, J. D., Fisher, J. W.: Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoietin in renal failure. Kidney Int., 25, 430 (1984).
13. Mcdougall, I. C., Roberts, D. E., Neubert, P., Dharmasena, A. D., Coles, G. A., Williams, J. D.: Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet, i, 425 (1989).
14. Ateshkadi, A., Johnson, C. A., Oxton, L. L., Hammond, T. G., Bohenek, W. S., Zimmerman, S. W.: Pharmacokinetics of intraperitoneal, intravenous and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am. J. Kidney Dis., 21, 622 (1993).
15. Evans, J. H. C., Brocklebanc, J. T., Bowmer, C. J., Ng, P. C.: Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrol. Dial. Transplant., 6, 709 (1991).
16. Braun, A., Ding, R., Seidel, C., Fies, T., Kurtz, A., Scharer, K.: Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure. Pediatr. Nephrol., 7, 61 (1993).
17. Montini, G., Zacchello, G., Perfumo, F., Edefonti, A., Bassi, S., Cantaluppi, A., Sarchi, C., Cazzin, M., Ferrari, V., Boccazzi, A., Caringella, A., Cattarelli, D., Coppo, R., Longo, L., Sorino, P., Verrina, E., Gusmano, R.: Pharmacokinetics and hematologic response to administration of recombinant human erythropoietin in children undergoing long-term peritoneal dialysis: A multicenter study. J. Pediatr., 122, 297 (1993).
18. Egrie, J. C., Eschbach, J. W., Mc Guire, T., Aramson, D. W.: Pharmacokinetics of recombinant human erythropoietin (r Hu Epo) administration to hemodialysis (HD) patients. Abstract. Kidney Int., 33, 262 (1988).
19. Lim, V. S., De Gowin, R. L., Zavala, D., Kirchner, P. T., Abels, R., Perry, P., Fangman, J.: Recombinant human erythropoietin treatment in pre-dialysis patients. Ann. Int. Med., 110, 108 (1989).
20. Faulds, D., Sorkin, E.: Epoetin (Recombinant human erythropoietin): A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anemia of end-stage renal disease. Am. J. Kidney Dis., 14, 163 (1989).